NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

生物相似药相关的事业联盟:条件与契约内容 (2010~2020年)

Global Biosimilars Partnering Terms and Agreements 2010 to 2021

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品编码 939925
出版日期 内容资讯 英文 150+ Pages
订单完成后即时交付
价格
生物相似药相关的事业联盟:条件与契约内容 (2010~2020年) Global Biosimilars Partnering Terms and Agreements 2010 to 2021
出版日期: 2021年06月01日内容资讯: 英文 150+ Pages
简介

本报告提供生物相似药开发相关近来 (2010~2020年)的联盟交易的趋势相关分析,整体交易形成数量的变化,及财务方面 (付款条件) 的趋势,主要企业 (共25家公司) 的交易形成的动向,契约条件的趋势,各技术、治疗标的趋势等调查,近几年主要的联盟交易 (共140件)等详细资讯汇整,为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 生物相似药相关的交易形成的趋势

  • 简介
  • 生物相似药相关的交易形成:近几年趋势
  • 生物相似药相关的交易形成:最活跃的企业
  • 生物相似药相关的交易形成:各交易类型
  • 生物相似药相关的交易形成:各治疗领域
  • 生物相似药相关的交易形成:各业界
  • 生物相似药相关的事业联盟:交易条件
    • 交易总额
    • 预付款金
    • 阶段性付款
    • 权利金费率
  • 生物相似药相关的交易结构
    • 案例研究 (1)~(3)

第3章 生物相似药相关的代表性交易

  • 简介
  • 生物相似药相关的主要的联盟交易:各契约金额

第4章 生物相似药相关的契约缔结上最活跃的企业

  • 简介
  • 在生物相似药的领域最活跃的企业:交易总额
  • 主要企业的简介

第5章 生物相似药的契约文件名录

  • 简介
  • 生物相似药相关的资本交易趋势:可阅览契约文章的交易的情况

第6章 生物相似药相关的交易形成:各技术种类

第7章 事业联盟的资源中心

  • 线上联盟
  • 联盟活动
  • 参考文件:交易形成趋势的相关

第7章 合作伙伴资源中心

  • 线上联盟
  • 联盟活动
  • 交易决策更多讯息

附录

  • 附录 (1):生物相似药相关的联盟交易一览,各企业名 (ABC顺序,2014~2020年)
  • 附录 (2):生物相似药相关的联盟交易一览,各开发阶段 (2014~2020年)
  • 附录 (3):生物相似药相关的联盟交易一览,各交易类型 (2014~2020年)
  • 附录 (4):生物相似药相关的联盟交易一览,各治疗领域 (2014~2020年)
  • 附录 (5):交易的种类定义

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: CP2124

The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides comprehensive understanding and unprecedented access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Biosimilars partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Biosimilars partnering contract documents

Top Biosimilars deals by value

The Global Biosimilars Partnering Terms and Agreements report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
  • The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2010.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.

Report scope

  • Global Biosimilars Partnering Terms and Agreements 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.

Global Biosimilars Partnering Terms and Agreements 2010 to 2021 includes:

  • Trends in Biosimilars dealmaking in the biopharma industry since 2010
  • Analysis of Biosimilars deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 170 Biosimilars deal records and contract documents where available
  • The leading Biosimilar deals by value since 2010
  • Most active Biosimilars dealmakers since 2010
  • The leading Biosimilars partnering resources

In Global Biosimilars Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Biosimilars Partnering Terms and Agreements 2010 to 2021 provides the reader with the following key benefits:

  • In-depth understanding of Biosimilars deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to Biosimilars deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Biosimilars deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Biosimilars deals by value since 2010
  • Identify the most active Biosimilars dealmakers since 2010
  • Detailed access to actual Biosimilars contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Biosimilars agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biosimilars dealmaking

  • 2.1. Introduction
  • 2.2. Biosimilars partnering over the years
  • 2.3. Most active biosimilars dealmakers
  • 2.4. Biosimilars partnering by deal type
  • 2.5. Biosimilars partnering by therapy area
  • 2.6. Deal terms for biosimilars partnering
    • 2.6.1 Biosimilars partnering headline values
    • 2.6.2 Biosimilars deal upfront payments
    • 2.6.3 Biosimilars deal milestone payments
    • 2.6.4 Biosimilars royalty rates

Chapter 3 - Leading Biosimilars deals

  • 3.1. Introduction
  • 3.2. Top Biosimilars deals by value

Chapter 4 - Most active Biosimilars dealmakers

  • 4.1. Introduction
  • 4.2. Most active Biosimilars dealmakers
  • 4.3. Most active Biosimilars partnering company profiles

Chapter 5 - Biosimilars contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Biosimilars contracts dealmaking directory

Chapter 6 - Biosimilars dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Biosimilars deals by company A-Z
  • Appendix 2 - Biosimilars deals by stage of development
  • Appendix 3 - Biosimilars deals by deal type
  • Appendix 4 - Biosimilars deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Biosimilars partnering since 2010
  • Figure 2: Active biosimilars dealmaking activity since 2010
  • Figure 3: Biosimilars partnering by deal type since 2010
  • Figure 4: Biosimilars partnering by disease type since 2010
  • Figure 5: Biosimilars partnering by technology type since 2010
  • Figure 6: Biosimilars deals with a headline value
  • Figure 7: Biosimilars deals with an upfront value
  • Figure 8: Biosimilars deals with a milestone value
  • Figure 9: Biosimilars deals with a royalty rate value
  • Figure 10 Top biosimilars deals by value since 2010
  • Figure 11: Most active biosimilars dealmakers since 2010
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events